Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

Post by jopatcloon Jul 12, 2024 11:00am
74 Views
Post# 36130145

From George Adams ⬇️🚀.👀

From George Adams ⬇️🚀.👀
 From George Adams
 
Here is some background:
 
1. Ascend provides a platform to optimize workflow in echocardiography units in a large number of hospitals in North America.
2. The Company announced last year a collaboration with Ascend Cardiovascular (see NR 2023-08-10) and the creation of a prototype integrated product for 3D-scans later in the year.
3. Today, we announced the Company has expanded the relationship to include 2D and 3D studies and that Ascend will help with sales of both 2D and 3D systems.
4. In addition, we have been invited to be part of Ascend’s “next-generation” platform, called Catalyst, which is under development.
5. The more the VMS+ can be seamlessly used by echocardiolographers, the better as the COVID pandemic along with the aging population continues to create more and more patients with heart conditions that need to be assessed and monitored.
 
Thank you for your interest and support, as the Company continues to improve cardiac diagnostics for everyone, everywhere and especially for children born with heart defects,
 
Regards,
 
Dr. George Adams ICD.D
Executive-Chairman
Ventripoint Diagnostics Ltd.
TSXV-VPT
<< Previous
Bullboard Posts
Next >>